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Objective: Recently adipokines have been implicated in the regulation of immune and inflammatory responses in
autoimmune disease. To investigate the role of adipokines in adult and pediatric patients with newly diagnosed
dermatomyositis (DM), we analyzed peripheral blood and skeletal muscle gene expression of four adipokines:
visfatin, leptin, adiponectin and resistin.
Methods: Peripheral blood mononuclear cells (PBMCs) were collected for 21 adult DM, 26 juvenile DM, 5 non-disease
adult controls, and 6 non-disease pediatric controls at two time points: baseline and 6 months. Muscle biopsies from 5
adult DM patients and 5 non-disease adult controls were collected at baseline. Similarly, muscle biopsies from 7 juvenile
DM patients and 5 non-disease pediatric controls were collected at baseline. The gene expression levels of leptin,
adiponectin, resistin, visfatin and related inflammatory cytokines, IL-6, TNF- α, and housekeeping genes GAPDH, B2M,
and ACTB were generated using a custom RT2 Profiler PCR Array.
Results: Visfatin gene expression levels in peripheral blood were significantly higher in newly diagnosed adult DM
cases compared to non-disease controls (P = 0.004) and these levels correlated with baseline clinical parameters
such as age (r = 0.34, P = 0.020), male sex (r = −0.35, P = 0.017), prednisone use (r = −0.42, P = 0.006), and DMARD
use (r = 0.35, P = 0.025). No significant association was found between change in visfatin gene expression levels
and change in disease activity measures. While visfatin gene expression was significantly up-regulated in muscle
tissue of juvenile DM patients (P = 0.028), in adult DM patients only a trend towards significance was observed
(P = 0.08). Also, muscle gene expression levels of resistin were significantly elevated in both adult and juvenile
DM patients compared respectively to non-disease adult and pediatric controls. Furthermore, an association
between peripheral blood resistin gene expression and DM disease activity, including global, muscle, and
extra-skeletal disease activity was also observed.
Conclusion: Peripheral blood visfatin gene expression and muscle resistin gene expression are significantly
increased in newly diagnosed adult DM patients. Further longitudinal studies should explore the possibility of
using gene expression levels of adipokines such as visfatin and resistin as novel clinical diagnostic biomarkers
in DM.
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The idiopathic inflammatory myopathies (IIMs) are a
heterogeneous group of chronic acquired disorders char-
acterized by proximal muscle weakness and muscle in-
flammation [1,2]. In adults, dermatomyositis (DM) and
polymyositis (PM) are common IIM conditions; in chil-
dren, juvenile DM is the most common IIM [3]. Adult
and juvenile DM are both characterized clinically by
proximal muscle weakness; muscle inflammation; and
particular rashes in the face or other extensor surfaces
[4]. While some overlap between disease characteris-
tics exist, adult and juvenile DM are considered separ-
ate entities with variable features [5]. For example,
adults with DM are at an increased risk of malignancy
and are more likely to develop interstitial lung disease.
Meanwhile juvenile DM is associated with increased
vasculopathy and calcinosis.
Pharmacological therapy for DM consists of cortico-
steroids and disease-modifying antirheumatic drug
(DMARDS) [6,7]. Some patients with DM respond
poorly to conventional treatment and many experience
morbidity from side effects [8]. Therefore, there is a
need for safer and more effective treatment in these
diseases. While the etiology of DM is still unknown, in-
vestigations into their pathogenesis have confirmed the
involvement of many pro-inflammatory cytokines. Con-
sequently, one potential therapeutic approach would be
to target individual cytokines that contribute to the
pathogenesis of DM [8]. Recently it has been revealed
that peripheral blood mononuclear cells (PBMCs) and
muscle tissue of DM patients exhibit an interferon
(IFN) gene expression signature which correlated with
disease activity [8,9]. Interferons are potent cytokines
that function to prevent viral replication (IFN-α and
IFN- β), and mediate Th1 immune responses (IFN-γ).
Therefore, studies should assess other cytokine path-
ways and evaluate their utility for monitoring disease
activity and therapeutic response in patients with DM.
Adipokines, cytokines produced mainly by adipocytes,
have been implicated in the regulation of immune and
inflammatory responses. In fact, it is currently widely
accepted that adipokines produced and secreted by
white adipose tissue (WAT) are responsible for the
chronic inflammatory state of visceral obesity [10].
While adipocytes are the most abundant cells in WAT,
other cell types such as macrophages are also present
[11]. Similarities between adipocytes and macrophages
are observed, and pre-adipocytes can differentiate into
macrophages [12]. Furthermore, although lymphocytes
are not a constituent of WAT, there is often a close
physical proximity between lymphocytes and WAT. For
example, lymph nodes are generally surrounded by peri-
capsular adipose tissue [13,14]. Therefore, studies now
support the idea of cross-talk between lymphocytes andadjacent adipocytes through a variety of adipokines. To
date, the most heavily studied adipokines have been lep-
tin, adiponectin, resistin, and visfatin. These adipokines
are considered to be primarily pro-inflammatory factors,
except for adiponectin which has been described to have
anti-inflammatory properties [15].
Adipokines have also been implicated in vascular
homeostasis [16]. In fact, certain adipokines have been
found to be deregulated in patients with cardiovascular
diseases and hypertension [16]. While the mechanisms
underlying these associations remain unclear, it is
thought that the crosstalk between adipose tissue and
blood vessels is vital to vascular homeostasis. Studies
have demonstrated that perivascular adipose tissue can
produce many adipokines that contribute to the regu-
lation of vascular function and local inflammation [16].
These findings are relevant to DM since vasculopathic
changes are important features of DM. Changes in the
nailfold capillaries, including dilatation, occlusion, ar-
boreal loops, hemorrhages and vessel drop-out are well
documented in DM, especially in juvenile DM [17].
The association between visceral obesity and chronic in-
flammation introduced the idea that adipokines may con-
tribute to the pathogenesis of inflammatory-autoimmune
conditions such as rheumatoid arthritis (RA) and sys-
temic lupus erythematosus (SLE). While there are con-
flicting reports, most studies have shown increased
serum levels of leptin, adiponectin, and resistin in both
RA and SLE [18-26]. In the case of DM, the role of adi-
pokines in the modulation of immune response has not
been studied as extensively. Currently, only one report
has evaluated serum resistin levels in DM [27]. In this
study, Filkova et al. demonstrated elevated resistin levels
in serum of patients with DM [27]. Thus, at present time
most studies in inflammatory-autoimmune diseases have
measured adipokine levels in serum, which may be un-
reliable to evaluate cytokine pathway activation [8,28].
Immunohistochemical studies for determining serum
cytokine levels can be confounded by technical and bio-
logical limitations, including non-specific immunoreac-
tivity, transient expression and low concentration [28].
Therefore, researchers have turned to PCR-based stud-
ies to examine cytokine gene expression in PBMCs
(comprised of monocytes/macrophages, B and T lym-
phocytes, and natural killer cells) and have demonstrated
that the real-time PCR technique is an alternative and
potentially more precise way to evaluate cytokine
pathways [8]. In fact, recent studies have documented
the association of adipokines with metabolic syndrome
at the gene expression level instead of the protein
level [29].
The pathogenic role played by adipokines in
inflammatory-autoimmune disorders such as ju-
venile DM and adult DM should be further explored at
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Therefore, we determined peripheral blood and skeletal
muscle gene expression levels of leptin, adiponectin, resis-
tin and visfatin in adult and pediatric patients with DM in
comparison to non-disease controls at two different time-
points and investigated their relation to clinical parame-
ters and to disease activity measures.
Materials and methods
Patient characteristics
Blood and muscle biopsy samples were collected from
pediatric and adult patients with newly diagnosed DM,
sequentially recruited from clinics in the Mayo Clinic Div-
ision of Rheumatology, and Department of Medicine and
Pediatrics and Adolescent Medicine (Rochester, MN). All
patients met Bohan and Peter’s criteria for DM [30]. We
collected PAXgene vacutainers for 21adult DM, 26 juvenile
DM, and for adult (n = 5), and pediatric (n = 6) non-disease
controls at two different time points: baseline and 6-month
follow-up visit. Muscle biopsies for 5 adult DM patients
from the same blood cohort were collected at baseline visit
and 5 non-disease muscle biopsies served as controls. Simi-
larly, muscle biopsies from 7 juvenile DM patients and 5
non-disease pediatric controls were collected. Disease
activity was determined by the Myositis Disease Activity
Assessment Visual Analogue Scales (MYOACT) Scoring
System at time of blood draw at baseline and at the
6 month follow-up.
This study was carried out in accordance with research
protocols approved by Institutional Review Boards of the
Mayo Clinic. Patients and legal guardians signed in-
formed consent and/or assent, and samples were de-
identified in the laboratory.
RNA isolation and quantification of adipokine gene
expression
Total RNA was isolated from whole blood using PAXgene
tubes with on-column DNase treatment according to manu-
facturer’s protocol (PreAnalytiX). Muscle was homogenizedTable 1 Baseline characteristics of patients with juvenile and
Characteristic JDM
N 26
Age in years 10.1 (3
Male sex (%) 10 (38
Time from Diagnosis date to baseline visit, years 0.05 (0
Prednisone use (%) 9 (43%
DMARD use (%) 7 (33%
Global Disease Activity (0–100) 42.5 (2
Muscle Disease Activity (0–100) 23.5 (0
Global Extra-Skeletal Muscle Disease Activity (0–100) 35 (2–
*Values are presented as median (range) unless indicated otherwise. JDM = juvenileusing a PowerGen 700 (Fisher Scientific) and RNA was
isolated using Trizol (Invitrogen) and an RNeasy Mini Kit
(Qiagen) with on-column DNase treatment. The mRNA
gene expression levels of leptin, adiponectin, resistin, vis-
fatin, IL6, TNFα, and housekeeping genes GAPDH, B2M,
and ACTB were generated using a custom RT2 Profiler
PCR Array run on an ABI 7900HT (Mayo Clinic Medical
Genome Facility). Genes were normalized to the mean of
three housekeeping genes and to experimental controls
and were expressed as relative quantification.Statistical analysis
Data are expressed as the median (range), where indicated.
A Wilcoxon rank sum test was performed for comparisons
between two groups (e.g. adult DM versus adult controls;
juvenile DM versus pediatric controls; and adult DM versus
juvenile DM). A paired comparison test was performed to
compare adipokine gene expression levels between baseline
and 6 months. Spearman correlation coefficients were used
to correlate any two variables. P values less than 0.05 were
considered statistically significant. Analyses were performed
using the SAS version 9.3 (SAS Institute Inc., Cary, NC,
USA) statistical package.Results
Baseline characteristics
The characteristics of patients included in the study are
given in Table 1. Our study included 21 adult and 26
juvenile DM patients diagnosed by Bohan and Peter’s cri-
teria for DM. The median (range) age (years) and gender
were as follows: Juvenile DM 10.1(3.2-17.1) (38% male)
and adult DM 53.0(20.0-79.0)(19% male). All adult DM
and control subjects were Caucasian. Ethnicity in the
juvenile DM group comprised; 77% Caucasian, 8% African
American, 4% American Indian, 4% Pacific Islander, and
8% other. In terms of medication use at baseline, 70% of
adult DM and 43% of juvenile DM cases were receiving
prednisone or an equivalent, while 48% of adult DM andadult dermatomyositis*
DM JDM and DM
21 47
.2-17.0) 53.0 (20.0-79.0) 16.7 (3.2-79.0)
%) 4 (19%) 14 (30%)
–14.49) 0.17 (0–2.85) 0.10 (0–14.49)
) 14 (70%) 23 (56%)
) 10 (48%) 17 (40%)
–81) 32 (3–80) 39 (2–81)
–83) 33 (0–83) 25 (0–83)
73) 32 (0–66) 33 (0–73)
dermatomyositis; DM = dermatomyositis; N = number.
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of the DM patients had been diagnosed with malignancy.Adipokine gene expression levels in peripheral blood
Gene expression levels of visfatin (P = 0.004) in peripheral
blood were significantly elevated in adult DM patients when
compared to non-disease adult controls (Table 2). Further-
more, gene expression levels of IL-6 displayed a non-
statistically-significant trend toward lower levels in adult
DM compared to non-disease adult controls (P = 0.06).
Gene expression levels of TNF- α (P < 0.001) and adipo-
nectin (P = 0.014) in peripheral blood were significantly
lower in pediatric DM patients when compared to non-
disease pediatric controls (Table 3). While gene expression
levels of visfatin were lower in pediatric DM compared to
non-disease pediatric controls, the difference did not
reach significance (P = 0.05). Gene expressions levels of
visfatin were increased in peripheral blood of adult DM
when compared to juvenile DM (P = 0.017). Also, gene ex-
pressions levels of IL-6 (P < 0.001) and leptin (P < 0.001)
were lower in peripheral blood of adult DM when com-
pared to juvenile DM.Adipokine gene expression levels in muscle tissue
Muscle gene expression levels of IL-6 (P = 0.047) and
resistin (P = 0.047) were significantly higher in adult DM
patients when compared to non-disease controls (Table 2).
While muscle gene expression levels of visfatin were
higher in adult DM compared to non-disease adult con-
trols, the difference failed to reach significance (P = 0.08).
Muscle gene expression levels of visfatin (P = 0.028) and
resistin (P = 0.012) were significantly higher in pediatric
DM patients compared to non-disease pediatric con-
trols (Table 3). While gene expression levels of IL-6 in
muscle were higher in adult DM compared to pediatric
DM, the difference did not reach significance (P = 0.09).Table 2 Differences in peripheral blood and muscle gene expre
patients and non-disease adult controls*
Peripheral blood
Adult DM Non-disease adult controls P Va
(N = 21) (N = 5)
Leptin 0.7 (0.6, 0.8) 0.8 (0.7, 0.8) 0.49
Adiponectin 0.1 (0.1, 12.1) 0.2 (0.0, 12.4) 0.63
Resistin 1.4 (0.9, 2.8) 0.6 (0.5, 2.5) 0.18
Visfatin 1.9 (1.7, 2.5) 0.3 (0.2, 1.1) 0.00
IL-6 0.4 (0.3, 0.7) 1.4 (0.7, 1.6) 0.06
TNF-α 0.7 (0.5, 0.8) 0.8 (0.7, 1.5) 0.28
*Values are presented as median (25th percentile, 75th percentile). Gene expressio
P-value is from Wilcoxon rank sum test.Correlation between baseline adipokine gene expression
levels in peripheral blood and baseline clinical parameters
Baseline blood cell gene expression levels of IL-6 corre-
lated with age (r = −0.64, P < 0.001) and prednisone use
(r = 0.34, P = 0.03) (Table 4). Baseline blood cell gene
expression levels of visfatin correlated with age (r =
0.34, P = 0.02), male sex (r = −0.35, P = 0.02), prednis-
one use (r = −0.42, P = 0.006), and DMARD use (r =
0.35, P = 0.02).
Correlation between baseline adipokine gene expression
levels in peripheral blood and baseline disease activity
measures
Baseline blood cell gene expression levels of IL-6 corre-
lated with muscle disease activity (r = −0.30, P = 0.04)
(Table 4). Baseline blood cell gene expression levels of
resistin correlated with global extra-skeletal muscle dis-
ease activity (r = 0.29, P = 0.046), muscle disease activity
(r = 0.50, P < 0.001), and global disease activity (r = 0.51,
P < 0.001).
Change between baseline and 6 months in adipokine
gene expression levels in peripheral blood
No significant differences (P > 0.05) were observed for
the changes between baseline and 6 months in adipo-
kine gene expression levels in peripheral blood of adult
DM patients (Table 5). Meanwhile, in juvenile DM pa-
tients, only the change between baseline and 6 months
in peripheral blood gene expression of IL-6 was signifi-
cant (P =0.04) (Table 5).
Correlation between change in adipokine gene
expression levels in peripheral blood and change in
disease activity measures
No significant associations (P > 0.05) between change
from baseline to 6 months in adipokine gene expres-
sion levels in peripheral blood and change in disease
activity measures were observed (Table 6). However, assion levels of adipokines between adult dermatomyositis
Muscle
lue Adult DM Non-disease adult controls P Value
(N = 5) (N = 5)
1.5 (0.9, 2.5) 1.4 (0.5, 1.9) 0.60
1.7 (0.9, 4.6) 1.3 (0.8, 2.0) 0.60
23.2 (7.7, 40.4) 2.6 (2.5, 7.4) 0.047
4 1.9 (1.8, 2.7) 1.0 (1.0, 1.1) 0.08
2.9 (1.7, 4.0) 1.0 (0.8, 1.1) 0.047
1.8 (1.1, 2.4) 1.0 (0.9, 1.2) 0.25
n levels of adipokines were normalized to the mean of age-matched controls.
Table 3 Differences in peripheral blood and muscle gene expression levels of adipokines between juvenile
dermatomyositis patients and non-disease pediatric controls*
Peripheral blood Muscle
JDM (N = 26) Non-disease pediatric
controls (N = 6)
P Value JDM (N = 7) Non-disease pediatric
controls (N = 5)
P Value
Leptin 1.2 (1.0, 1.6) 1.3 (0.7, 2.8) 0.96 0.6 (0.3, 1.3) 1.4 (0.5, 1.9) 0.37
Adiponectin 0.1 (0.1, 0.2) 1.2 (0.1, 4.0) 0.014 2.6 (0.4, 7.7) 1.3 (0.8, 2.0) 0.46
Resistin 0.9 (0.6, 1.5) 1.0 (0.7, 1.5) 0.60 15.9 (10.5, 18.4) 2.6 (2.5, 7.4) 0.012
Visfatin 1.4 (1.0, 2.1) 2.1 (1.7, 2.5) 0.05 2.0 (1.4, 3.0) 1.0 (1.0, 1.1) 0.028
IL-6 1.2 (0.8, 1.5) 1.2 (0.6, 1.6) 0.92 1.6 (0.7, 1.7) 1.0 (0.8, 1.1) 0.22
TNF-α 0.6 (0.4, 0.7) 1.0 (0.9, 1.4) <0.001 2.2 (1.1, 3.0) 1.0 (0.9, 1.2) 0.09
*Values are presented as median (25th percentile, 75th percentile). Gene expression levels of adipokines were normalized to the mean of age-matched controls.
P-value is from Wilcoxon rank sum test.
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association between change in gene expression levels
of IL-6 in peripheral blood and change in global extra-
skeletal muscle disease activity (r = 0.49, P = 0.05).
Discussion
In this study, we investigated whether blood and
muscle gene expression levels of certain adipokines are
deregulated in adult and pediatric patients with DM.
Our results indicate that genes of certain adipokines
are significantly differentially expressed between adult
DM and non-disease adult controls; and between ju-
venile DM and non-disease pediatric controls. Gene
expression of visfatin is significantly up-regulated in
peripheral blood of adult DM patients- compared to
non-disease adult controls, while gene expression of
TNF-α and adiponectin are down-regulated in periph-
eral blood of pediatric DM compared to non-disease
pediatric controls. Additionally, our findings suggestTable 4 Correlations between baseline peripheral blood gen
parameters, and baseline disease activity measures*
Age Male sex Prednisone use DMARD use
Leptin −0.74 0.01 0.23 0.10
P < 0.001 P = 0.93 P = 0.14 P = 0.54
Adiponectin 0.07 −0.07 −0.26 0.21
P = 0.62 P = 0.63 P = 0.10 P = 0.18
Resistin 0.25 0.12 −0.34 −0.01
P = 0.09 P = 0.44 P = 0.027 P = 0.95
Visfatin 0.34 −0.35 −0.42 0.35
P = 0.020 P = 0.017 P = 0.006 P = 0.025
IL-6 −0.64 0.03 0.34 −0.07
P < 0.001 P = 0.85 P = 0.029 P = 0.66
TNF-α 0.12 0.003 0.28 0.22
P = 0.41 P = 0.98 P = 0.07 P = 0.16
*Values are Spearman correlations, followed by P-values.that there are adipokine gene expression differences in
adult DM versus juvenile DM in peripheral blood.
Gene expression of visfatin was up-regulated, while IL-
6 and leptin were down-regulated, in peripheral blood
of adult DM when compared to juvenile DM.
Furthermore, we explored whether baseline gene ex-
pression levels of adipokines in peripheral blood asso-
ciate with baseline clinical parameters. Interestingly,
baseline gene expression of visfatin in peripheral blood,
which is up-regulated in adult DM, correlated significantly
with clinical parameters at baseline such as age, male sex,
prednisone use, and DMARD use. Moreover, baseline
peripheral blood resistin gene expression significantly
correlated with DM disease activity, including global,
muscle, and extra-skeletal disease activity. However,
when exploring the predictive value of gene expression
of adipokines in peripheral blood for change in disease ac-
tivity measures by performing Spearman correlations, no








P = 0.81 P = 0.07 P = 0.68
−0.15 −0.01 −0.06
P = 0.31 P = 0.95 P = 0.70
0.29 0.50 0.50
P = 0.046 P < 0.001 P < 0.001
−0.20 −0.019 −0.11
P = 0.17 P = 0.90 P = 0.46
−0.03 −0.30 −0.14
P = 0.87 P = 0.042 P = 0.34
−0.11 −0.25 −0.23
P = 0.47 P = 0.09 P = 0.11
Table 5 Change between baseline and 6 months in adipokine gene expression levels in peripheral blood of adult DM
and JDM patients*
Adult DM JDM
Baseline 6 months Difference P-value Baseline 6 months Difference P-value
Leptin 0.66 (0.25) 0.5 (0.22) −0.16 (0.37) 0.26 1.14 (0.29) 0.81 (0.39) −0.34 (0.54) 0.12
Adiponectin 11.8 (17.5) 3.2 (8.72) −8.55 (17.25) 0.20 2.04 (5.23) 6.08 (16.6) 4.04 (17.82) 0.54
Resistin 3.08 (2.65) 2.84 (4.82) −0.24 (4.7) 0.89 1.13 (0.82) 1.44 (1.98) 0.32 (2) 0.66
Visfatin 2.25 (1.01) 2.62 (1.5) 0.37 (1.43) 0.48 1.76 (0.87) 2.24 (1.55) 0.48 (1.77) 0.47
IL-6 0.48 (0.46) 0.42 (0.24) −0.07 (0.42) 0.67 1.23 (0.73) 0.71 (0.3) −0.52 (0.58) 0.04
TNF-α 0.61 (0.3) 0.67 (0.4) 0.06 (0.34) 0.65 0.6 (0.17) 0.63 (0.27) 0.03 (0.29) 0.76
*Values are presented as mean (SD). Gene expression levels of adipokines were normalized to the mean of age-matched controls. P-value is from paired
comparison test.
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adipokines in peripheral blood, our study also observed
deregulation in gene expression of certain adipokines
in muscle tissue. Gene expressions of IL-6 and resistin
were significantly up-regulated in muscle tissue of
adult DM patients compared to non-disease adult con-
trols. Only a non-statistically-significant trend toward
elevation of gene expression of visfatin in muscle tissue
was observed in adult DM compared to non-disease
controls. Moreover, gene expression of visfatin was sig-
nificantly up-regulated in muscle tissue of pediatric
DM patients compared to non-disease pediatric con-
trols. Therefore, our over-all findings suggest the role
of visfatin should be further explored in inflammatory-
autoimmune disorders.
Visfatin, also known as pre-B-cell colony enhancing fac-
tor and nicotinamide phosphoribosyltransferase (NAMPT),
is an adipokine produced predominantly by visceral fat that
stimulates insulin signaling [18]. Serum levels of visfatinTable 6 Correlations between change in peripheral blood











Leptin −0.25 −0.11 −0.06
P = 0.34 P = 0.70 P = 0.84
Adiponectin 0.16 −0.01 −0.05
P = 0.56 P = 0.96 P = 0.85
Resistin −0.23 0.42 0.14
P = 0.39 P = 0.10 P = 0.61
Visfatin −0.24 −0.24 −0.22
P = 0.36 P = 0.37 P = 0.42
IL-6 0.49 −0.03 0.29
P = 0.05 P = 0.90 P = 0.28
TNF-α −0.38 0.01 −0.08
P = 0.15 P = 0.97 P = 0.76
*Values are Spearman correlations, followed by P-values.correlate with the amount of visceral fat and are increased
in patients with obesity and type- 2 diabetes [31,32]. While
visfatin is mainly produced by visceral adipose tissue, stud-
ies have demonstrated that it is also produced by several
types of immune cells [33,34]. In fact, visfatin has been
shown to have pro-inflammatory and immunomodulatory
properties, and therefore is currently regarded as an im-
portant mediator of innate immunity and inflammation.
Visfatin is synthesized in response to inflammation and
up-regulates the production of pro-inflammatory and anti-
inflammatory cytokines such as TNF-α, IL-6, IL-1β, IL-10
and IL-1Ra [35]. Also, visfatin promotes activation of T-
cells by up-regulating the expression of co-stimulatory
molecules such as CD40, CD54 and CD80 on monocytes
[35]. There is evidence as well that visfatin serves as a po-
tent chemotactic factor for monocytes and lymphocytes
[35]. Lastly, visfatin, in conjunction to IL-7, can affect early
B and T-lymphocyte development [35].
While reports on visfatin have focused heavily on its
function on the metabolic syndrome and obesity, recently
there have been reports on its association with inflamma-
tory diseases. In both RA and SLE, serum levels of visfatin
are increased compared to healthy controls [20,36]. Fur-
thermore, in RA, serum levels of visfatin correlated with
the degree of inflammation, severity of disease, and joint
damage [18,36]. Moreover, inhibition of visfatin in a
mouse model of RA showed reduced systemic and local
inflammatory markers of arthritis, including reduced
serum levels of IL-6, and a marked reduction in the num-
ber of Th17 cell, as well, as in the number and activation
status of monocytes, macrophages, and neutrophils infil-
trating arthritic joints [37]. Therefore, there is potential
utility of targeting the visfatin gene for therapeutic inter-
vention in arthritis [37].
In search of novel cytokine pathways that could po-
tentially have utility for monitoring disease activity and
therapeutic response in patients with DM, we explored
the adipokine gene expression profile of adult and
pediatric DM patients. To our knowledge, this is the
first study to asses both peripheral blood and muscle
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DM. While resistin had been reported to be increased
in serum of DM patients by Filkova et al. [27], previous
to our study, it was unknown whether adipokine gene
expression levels in peripheral blood or muscle tissue
were deregulated in DM. While peripheral blood gene
expression levels of resistin were not found to be sig-
nificantly different between DM patients and controls,
we did observe that muscle gene expression levels of
resistin were significantly elevated in both adult and ju-
venile DM patients compared respectively to non-
disease adult and pediatric controls. Furthermore, our
study showed an association between peripheral blood
resistin gene expression and DM disease activity, includ-
ing global, muscle, and extra-skeletal disease activity.
Resistin is a member of cysteine-rich proteins called
“resistin-like molecules” or “found in inflammatory zone”
[15,38]. While originally described as an adipocyte-specific
hormone modulating insulin resistance in rodents, it is im-
perative to note that there are marked differences in the
source of production of resistin between humans and
rodents. In rodents, resistin is synthetized mainly by adipo-
cytes; however in humans, it is chiefly synthesized in circu-
lating monocytes and macrophages [15,38]. In humans,
therefore, resistin is thought to regulate metabolic pro-
cesses, adipogenesis, and inflammatory reactions. While the
role of resistin in the pathology of muscle tissue in DM
remains unknown, the association of resistin with muscle
tissue inflammation in DM patients advocates further re-
search in the area. Studies have demonstrated that resistin
expression is up-regulated by pro-inflammatory cytokines,
and in turn, resistin is able to induce the production of
TNF-α, IL-6, IL-12, and IL-1β [15,39]. In fact, it was re-
cently shown that resistin induces the production of these
pro-inflammatory cytokines by acting as a competitive
agonist for TLR-4, which is expressed in immune cells and
immature muscle cell precursors [40]. These findings
suggest that resistin may participate in muscle tissue dam-
age by inducing pro-inflammatory cytokines through an
interaction with TLR-4.
Because of the potential for transient expression and
low concentration of cytokines, we opted to measure the
adipokine gene profile in patients with DM at the gene ex-
pression level, and not the protein level. Previous studies
have shown that gene expression profiling of PBMCs can
be useful to identify distinct patterns of gene expression
that distinguish patients with inflammatory-autoimmune
disorders from non-disease controls [8,9,41]. Though our
study looked at gene expression concentrations of adipo-
kines in whole blood, instead of serum, we believe our
results are in line with previous studies in autoimmune-
inflammatory diseases demonstrating deregulation in
serum adipokines. Nevertheless, a limitation of this
study was the relatively small sample size. For thisreason, our data must be interpreted carefully. Further
studies should explore whether adipokines, such as vis-
fatin and resistin, may serve as potential biomarkers
for disease activity monitoring and therapeutic re-
sponse in DM.
Conclusion
Adipokines are mainly adipocyte-derived cytokines with
pro-inflammatory and immunomodulatory properties in
humans. Our study shows that gene expression levels of
visfatin are elevated in peripheral blood of adult DM pa-
tients, and that these levels are associated with baseline
clinical parameters such as age, sex, prednisone use and
DMARD use. Also, we demonstrate that muscle gene
expression levels of resistin are significantly elevated in
both adult and juvenile DM patients compared respect-
ively to non-disease adult and pediatric controls. Further-
more, an association between peripheral blood resistin
gene expression and DM disease activity, including global,
muscle, and extra-skeletal disease activity, was also seen.
Nevertheless, the role of adipokines, such as visfatin and
resistin, in the pathology of DM and their usefulness as
biomarkers for disease activity monitoring remains to be
elucidated.
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